Boonseong
2021-11-24
[财迷]
FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":874873612,"tweetId":"874873612","gmtCreate":1637763174799,"gmtModify":1637763174894,"author":{"id":3585729801280242,"idStr":"3585729801280242","authorId":3585729801280242,"authorIdStr":"3585729801280242","name":"Boonseong","avatar":"https://static.tigerbbs.com/246facebf009ccbd87b47e3e304c37ef","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":20,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[财迷] </span></p></body></html>","htmlText":"<html><head></head><body><p><span>[财迷] </span></p></body></html>","text":"[财迷]","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/874873612","repostId":1167653292,"repostType":4,"repost":{"id":"1167653292","kind":"news","pubTimestamp":1637762873,"share":"https://www.laohu8.com/m/news/1167653292?lang=&edition=full","pubTime":"2021-11-24 22:07","market":"us","language":"en","title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","media":"Benzinga","summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","content":"<p><b>Relief Therapeutics Holding SA's</b> collaborating partner <b>NRx Pharmaceuticals Inc</b> has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.</p>\n<ul>\n <li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>\n <li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.</li>\n <li>Therefore, the denial does not impede NRx's ability to seek drug approval.</li>\n <li>Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>\n <li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.<i>.</i></li>\n <li><b>Price Action:</b> NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167653292","content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":309,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/874873612"}
精彩评论